What changed in Vertex Pharmaceuticals Inc / Ma's latest annual report
In the year ended 31 Dec 2025, Vertex Pharmaceuticals Inc / Ma's revenue rose 8.9% to USD 12.00bn, from USD 11.02bn; total liabilities rose 13.9% to USD 6.98bn, from USD 6.12bn; total assets rose 13.8% to USD 25.64bn, from USD 22.53bn.
Year ended 31 Dec 2025. Source: 10-K filed 13 Feb 2026, read it on SEC EDGAR.
USD 11.02bn to USD 12.00bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 11.02bn | 12.00bn | Up 8.9% |
| Net income | -535.60m | 3.95bn | Not comparable |
| Total assets | 22.53bn | 25.64bn | Up 13.8% |
| Total liabilities | 6.12bn | 6.98bn | Up 13.9% |
| Cash and cash equivalents | 4.57bn | 5.08bn | Up 11.3% |
| Shareholders' equity | 16.41bn | 18.67bn | Up 13.7% |
Questions people ask
Did Vertex Pharmaceuticals Inc / Ma's revenue grow last year?
Revenue grew 8.9%, from USD 11.02bn to USD 12.00bn in the year ended 31 Dec 2025.
Is Vertex Pharmaceuticals Inc / Ma profitable?
Yes. Net income was USD 3.95bn in the year ended 31 Dec 2025. The year before: a net loss of USD 535.60m.
How much cash and debt does Vertex Pharmaceuticals Inc / Ma have?
At its latest year end (31 Dec 2025), Vertex Pharmaceuticals Inc / Ma reported cash and cash equivalents of USD 5.08bn.
Where do these numbers come from?
From Vertex Pharmaceuticals Inc / Ma's own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Vertex Pharmaceuticals Inc / Ma?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Pharmaceutical Preparations companies
- Eli Lilly And CompanyCash and cash equivalents up 122.4%
- Johnson & JohnsonNet income up 90.6%
- AbbVie Inc.Revenue up 8.6%
- Merck & Co., Inc.Long-term debt up 35.7%
- Abbott LaboratoriesNet income down 51.3%
- Pfizer IncCash and cash equivalents up 9.5%
- Bristol-Myers Squibb CompanyShareholders' equity up 13.1%
- Regeneron Pharmaceuticals, Inc.Cash and cash equivalents up 25.3%